June 25, 2008
CSL Behring Awards LEAD Grants to Support Patient Group Advocacy Efforts
CSL Behring announced it has recently awarded seven grants totaling more than $90,000 to patient advocacy organizations in the United States. The seven grants represent the latest round of awards in the company's Local Empowerment for Advocacy Development (LEAD) program. CSL Behring is a global leader in the plasma protein biotherapeutics industry. LEAD grants support grassroots advocacy efforts by organizations committed to helping people with rare diseases who use plasma-derived and recombinant therapies to manage their health conditions. CSL Behring awards LEAD grants semiannually.
Grants were awarded to the following organizations in this round:
-- Hemophilia Foundation of Hawaii
-- Gateway Hemophilia Association (Missouri)
-- Lone Star Chapter of National Hemophilia Foundation (NHF, Texas)
-- Hemophilia of Indiana
-- Hemophilia Council of California
-- Immune Deficiency Foundation (IDF)
-- Alpha-1 Foundation
The Gateway Hemophilia Association, the Lone Star Chapter of the NHF and the Hemophilia Council of California all plan to advance state-wide standards of care or standards of service legislation. Hemophilia of Indiana is advocating a Medicaid policy change that will extend coverage to hospitals to defray the costs associated with administering blood clotting factors in hospital inpatient settings. Similarly, the Hemophilia Foundation of Hawaii is using the LEAD grant to seek the renewal of state legislation that will assist those in need of insurance copayment support. The IDF is promoting the Medicare IVIg Access Act, introduced by U.S. Senator John Kerry and U.S. Representative Kevin Brady. The Alpha-1 Foundation is supporting patient participation in the United for Lung Health Advocacy Day, a joint collaboration of several patient advocacy organizations calling for increased research efforts for respiratory disorders.
"The LEAD grant provided by CSL Behring will allow us to work directly with the Indiana Office of Medicaid Policy and Planning to create an inpatient Medicaid pass through," said Michelle Rice, Executive Director, Hemophilia of Indiana. "This will improve patient access to care by allowing hospitals in Indiana to treat Medicaid beneficiaries without having to absorb a loss for each individual."
"As leaders in advocacy CSL Behring collaborates with patient advocacy organizations on specific initiatives to improve access to care for life-saving plasma derived and recombinant therapies," said Dennis Jackman, Senior Vice President, CSL Behring. CSL Behring is proud to have initiated this program, and we look forward to awarding these grants on an ongoing basis to help organizations expand their advocacy initiatives."
LEAD grants are awarded biannually. The second round of 2008 grants will occur in October 2008. Applications, specific criteria for applying and more information about the LEAD program are available on the CSL Behring Web site at www.cslbehring.com/leadgrants.
Another facet of the LEAD Program is the Raise Your Voice! youth advocacy program. This program serves as an introduction to advocacy and government for young people. CSL Behring will collaborate with the Northern Ohio Hemophilia Foundation and Hemophilia of Michigan to develop youth advocacy sessions to train the next generation of advocates.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.